Inhibikase Therapeutics, Inc. Share Price
NASDAQ: IKT | Micro CapInhibikase Therapeutics, Inc. Stock Performance
Open $2.47 | Prev. Close $2.47 | Circuit Range N/A |
Day Range $2.42 - $2.52 | Year Range $1.33 - $2.53 | Volume 25,461 |
Average Traded $2.46 |
Inhibikase Therapeutics, Inc. Share Price Today
As of 11 August 2026, Inhibikase Therapeutics, Inc.'s share price is $2.46. The stock opened at $2.47, compared to its previous close of $2.47. During today's trading session, Inhibikase Therapeutics, Inc.'s share price traded between $2.42 and $2.52, with an average price of $2.47. Over the past 52 weeks, the stock has recorded a high of $2.53 and a low of $1.33. In terms of performance, Inhibikase Therapeutics, Inc.'s share price has risen by 20.00% over the last six months and is up 37.43% on a year-on-year basis.
Inhibikase Therapeutics, Inc. Share Price Chart
Inhibikase Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $241.84M | PE Ratio (TTM) -5.02 | Dividend Yield N/A |
EPS (TTM) $-0.49 | Revenue (TTM) -$51.97M | Return On Equity (TTM) -27.91% |
Profit Margin 92.85% | Debt to Equity 0.05 | Quarterly Earnings Growth YoY -194.19% |
Inhibikase Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Inhibikase Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Inhibikase Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.23 | $2.46 | +12.84% |
Jul 2026 | $2.04 | $2.18 | +7.44% |
Jun 2026 | $1.77 | $2.03 | +16.61% |
May 2026 | $1.87 | $1.74 | -7.94% |
Apr 2026 | $1.71 | $1.89 | +13.17% |
Mar 2026 | $1.94 | $1.67 | -18.54% |
Feb 2026 | $1.57 | $2.05 | +36.67% |
Jan 2026 | $2.04 | $1.50 | -27.18% |
Dec 2025 | $1.53 | $2.06 | +33.33% |
Nov 2025 | $1.34 | $1.54 | +4.39% |
Oct 2025 | $1.63 | $1.48 | -8.36% |
Sep 2025 | $1.79 | $1.61 | -9.78% |
IKT Share Price FAQs
What is Inhibikase Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Inhibikase Therapeutics, Inc. stock?
What is IKT's market capitalisation today?
What is IKT's net income for the last quarter?
What is the 5 year returns of IKT?
What is the high & low stock price of IKT today?
Can I buy IKT shares in India?